| Code | CSB-RA846610MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ulviprubart, targeting KLRG1 (Killer cell Lectin-like Receptor subfamily G member 1), an inhibitory receptor expressed on senescent and terminally differentiated immune cells. KLRG1 functions as a negative regulator of T cell and NK cell activation, binding to E-cadherin and N-cadherin on target cells to deliver inhibitory signals that limit immune responses. This receptor plays a critical role in immune senescence, chronic inflammation, and tumor immune evasion, as KLRG1-expressing cells exhibit reduced proliferative capacity and effector functions. Elevated KLRG1 expression has been associated with aging, chronic viral infections, autoimmune disorders, and cancer, where it contributes to immune exhaustion and impaired anti-tumor immunity.
Ulviprubart represents a therapeutic antibody designed to block KLRG1 signaling, thereby reinvigorating exhausted immune cells and enhancing anti-tumor responses. This biosimilar provides researchers with a valuable tool for investigating KLRG1-mediated immune regulation, studying mechanisms of immune senescence, and exploring potential therapeutic strategies for cancer immunotherapy and age-related immune dysfunction. The antibody enables detailed examination of KLRG1 blockade effects in preclinical models and cellular systems.
There are currently no reviews for this product.